A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Metastatic Colorectal Carcinoma
Interventions
DRUG

PF-05212384

PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly

DRUG

FOLFIRI regimen

The RP2D/MTD dose of FOLFIRI regimen every 2 weeks

BIOLOGICAL

Bevacizumab

5 mg/m\^2 every 2 weeks or 7.5 mg/m\^2 every 3 weeks

DRUG

FOLFIRI

Full dose FOLFIRI regimen every 2 weeks

Trial Locations (39)

28009

Hospital General Universitario Gregorio Marañón, Madrid

29303

Medical Group of the Carolinas - Hematology Spartanburg, Spartanburg

Spartanburg Regional Medical Center, Spartanburg

44109

Metrohealth Medical Center, Cleveland

89014

Comprehensive Cancer Centers of Nevada Research Department, Henderson

89052

Comprehensive Cancer Centers of Nevada, Henderson

89074

Comprehensive Cancer Centers of Nevada, Henderson

89128

Comprehensive Cancer Centers of NV, Las Vegas

89148

COmprehensive Cancer Centers of Nevada, Las Vegas

89169

Comprehensive Cancer Centers for Nevada, Las Vegas

90095

Ronald Reagan UCLA Medical Center, Los Angeles

Ronald Regan UCLA Medical Center, Drug Information Center, Los Angeles

TRIO-US Central Administration, Regulatory Management Only, Los Angeles

TRIO-US Central Administration, Los Angeles

TRIO_US, Los Angeles

UCLA Hematology Oncology Administrative Address, Los Angeles

Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles

90404

UCLA Hematology Oncology, Santa Monica

UCLA Santa Monica Medical Center & Orthopaedic Hospital, Santa Monica

91105

UCLA/Pasadena Healthcare, Pasadena

91328

West Valley Hematology/Oncology Med Group, Northridge

91355

UCLA/Santa Clarita Valley Cancer Center, Valencia

91361

UCLA Cancer Center, Westlake Village

92604

UCLA Hematology Oncology, Irvine

92835

St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton

93454

Central Coast Medical Oncology Corporation, Santa Maria

98101

Investigational Drug Services, Seattle

Virginia Mason Medical Center, Seattle

99208

Medical Oncology Associates, PS, Spokane

99216

Spokane Valley Cancer Center, Spokane Valley

99336

Kadlec Clinic Hematology and Oncology, Kennewick

99352

Kadlec Medical Center, Richland

Outpatient Imaging Center, Richland

90095-7349

Drug Management Only: UCLA West Medical Pharmacy, Attn Steven L. Wong, Pharm .D., Los Angeles

Drug Management Only: UCLA West Medical Pharmacy, Los Angeles

UCLA West Medical Pharmacy, Att: Steven L. Wong, Pharm D., Los Angeles

K1H 8 L6

The Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Cancer Centre, Toronto

08035

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01937715 - A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter